Retrovir Articles
FDA panel OKs Pfizer’s Selzentry for broader us in HIV naive patients, but drug criticized for its cost
12 October 2009
Thailand's HIV/AIDS drug resistance problem
29 September 2008
FDA starts safety review of GSK and B-MS HIV drugs
7 April 2008
SA MoH presents MTC HIV dual therapy plan
17 March 2008
Drug firms want two-year delay in US state's RFID law
11 February 2008
IFPMA chief outlines HIV/AIDS R&D efforts
10 December 2007
Indonesia's ARV program attacked
12 November 2007
Less side effects with switch from Combivir to Truvada
5 November 2007
Boeh Ing's Viramune may cut CV risk
6 August 2007
Pfizer's maraviroc fares well vs efavirenz
6 August 2007
Truvada/Sustiva cuts viral load vs Combivir/Sustiva
6 August 2007
Rwanda HIV/AIDS drug patent move
30 July 2007
GlaxoSmithKline in deal to supply HIV/AIDS drugs to Russia
25 September 2006
Off-label drug use defended by US think-tank
28 August 2006
Atripla approved by FDA for use in HIV-1 therapy
17 July 2006
FDA tentative appro of three-component AIDS drug
10 July 2006
GSK moves to help poorest fight HIV/AIDS
5 June 2006
Good efficacy for Gilead Sci's ARV combo
30 January 2006
GSK says combination HIV therapy increases treatment adherence
12 December 2005
Ranbaxy ARVs back on WHO list
22 August 2005
WHO, US FDA to share generic HIV/AIDS Rx data
22 August 2005
Aurobindo gets tentative appro for generic ARV
18 July 2005
South Africa awards ARV drug tenders
14 March 2005
More US FDA HIV/AIDS drug approvals "soon"
14 March 2005
GSK rebrands HIV/ AIDS drugs for Africa
28 February 2005
Gilead reports 48-wk data from HIV study
14 February 2005
US FDA OKs first ARV triple therapy for LDCs
31 January 2005
South African TAC "may seek efavirenz license"
22 November 2004
Ranbaxy withdraws generic antiretrovirals on quality concerns
15 November 2004
Ranbaxy files ANDA for antiretrovirals
8 November 2004
New Essential Drugs List for South Africa
27 September 2004
GSK: voluntary license for ARVs in South Africa
6 September 2004
Three Ranbaxy ARVs taken off WHO list
16 August 2004
WHO on HIV: publishes new guidelines on PMTCT, adds four drugs to pre-qualification list
26 July 2004
BI and GSK to co-package HIV drugs
19 July 2004
BI and GSK to co-package HIV drugs
19 July 2004
GSK ARVs placed on EU anti-diversion list
3 May 2004
GSK urges Nigeria to use ARV duty waiver
19 April 2004
Nigeria rolls out three Ranbaxy ARVs
12 April 2004
Syarikat to import AIDS drugs from Cipla
8 March 2004
GSK results in line with company guidance; shares fall on 16% drop in 4th-qtr income
23 February 2004
Abbott, B-MS, GSK lead growing HIV Rx mkt
16 February 2004
GSK moves to stop AIDS drug smugglers
5 January 2004
Indonesian state-owned drugmaker to produce five antiretroviral drugs
15 September 2003
US/S African on-line pharmacy offering cheap HIV/AIDS drugs
8 September 2003
Gilead starts Viread/Emtriva combi study
18 August 2003
S African HIV/AIDS civil disobedience halted
12 May 2003
GSK cuts HIV/AIDS Rx prices to LDCs again
5 May 2003
GSK AIDS drug patent "piracy" suit to re-open
31 March 2003
Activists fire shot at GSK over Trizivir study
17 March 2003
Update: GSK 2002 results boosted by 13% growth in US sales
17 February 2003
GlaxoSmithKline 2002 results boosted by 13% growth in US sales
17 February 2003
New ARVs
10 February 2003
China to make four HIV/ AIDS drugs from Jan
13 January 2003
WHO OKs Ranbaxy HIV/AIDS generics
29 July 2002
Viramune MTCT study has arm stopped early
22 July 2002
AIDS group demonstrates against GSK
22 July 2002
AHF files antitrust suit against GSK
8 July 2002
GSK to be sued over AIDS drug patents
8 July 2002
Revenues in 1st-qtr rise 30% at Shire
6 May 2002
WHO "essential list" of malaria, AIDS drugs
6 May 2002
Kenyan HIV/AIDS drug shortages hit patients
29 April 2002
WHO recommends AIDS drugs, makers
1 April 2002
Funding and approving new drugs in Israel's NHI basket
18 February 2002
GlaxoSmithKline 2001 pretax exceeds forecasts
18 February 2002
S African HIV/AIDS MTCT policy easing?
18 February 2002
S African states accept free Viramune from BI
4 February 2002
Triangle to file one, drop one HIV drug
28 January 2002
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
